Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
| Revenue (TTM) | $56.69B |
| Gross Profit (TTM) | $42.51B |
| EBITDA | $23.10B |
| Operating Margin | 34.60% |
| Return on Equity | 30.30% |
| Return on Assets | 10.20% |
| Revenue/Share (TTM) | $29.64 |
| Book Value | $21.86 |
| Price-to-Book | 7.46 |
| Price-to-Sales (TTM) | 5.36 |
| EV/Revenue | 6.14 |
| EV/EBITDA | 15.51 |
| Quarterly Earnings Growth (YoY) | -17.00% |
| Quarterly Revenue Growth (YoY) | 0.80% |
| Shares Outstanding | $1.90B |
| Float | $1.86B |
| % Insiders | 0.01% |
| % Institutions | 7.27% |
Volatility is currently expanding
A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading.
Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical trial failure from Novartis AG (NYSE:NVS) sent shockwaves through the sector.
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR study evaluating the drug in myotonic dystrophy type 1. The study did not show a statistically significant improvement over placebo on video hand opening time, a novel measure of hand myotonia that served as the trial's primary endpoint.
U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.
Amgen (AMGN) shares sold off after Novartis (NVS) failed to meet its primary endpoint in phase-3 trials. Diane King Hall offers more insight into the volatile moves in the healthcare space.
Novartis shares plunged after late-stage failures of pelacarsen and del-desiran, impacting its long-term growth outlook. Despite setbacks, Novartis reiterated 2025-2030 revenue growth guidance of 5-6% CAGR, aided by Rhapsido's phase 3 success in RMS. Rhapsido's positive data in relapsing multiple sclerosis offer partial offset, with potential for $3 billion+ in annual peak sales.
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Sandoz CEO Richard Saynor warned U.S. patients could ultimately bear the cost of threatened tariffs on imported generic drugs. Saynor said manufacturers facing steep tariffs could be forced to raise prices or stop supplying some medicines.
Novartis shares fell sharply on Tuesday after the Swiss drugmaker said its experimental treatment for myotonic dystrophy failed in a late-stage clinical trial, marking another setback for a pipeline that investors had been counting on to drive future growth. The stock fell about 10% following the announcement and has now lost more than 14% over the past five trading sessions.
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVS and any ticker you trade — then tracks every position and per-strategy win rate.
